Genetic Technologies Limited (ADR) (NASDAQ:GENE)

CAPS Rating: 1 out of 5

A biotechnology company, pursuing commercial opportunities in: out-licensing its non-coding patents globally; expanding genetic service-testing business in the Asia-Pacific Region; & supporting research projects in which it is already involved.

Results 1 - 7 of 7

Recs

0
Member Avatar KimLanners (< 20) Submitted: 9/8/2014 1:06:42 PM : Underperform Start Price: $0.66 GENE Score: +37.97

cash flow is not good

Recs

0
Member Avatar catalogna (< 20) Submitted: 8/27/2014 9:16:48 PM : Outperform Start Price: $0.65 GENE Score: -36.60

growing

Recs

0
Member Avatar red1582 (< 20) Submitted: 11/16/2012 11:52:49 AM : Underperform Start Price: $2.58 GENE Score: +126.81

100% Sell Signal
Gaped Down

Recs

1
Member Avatar MarkSmithJr777 (< 20) Submitted: 7/20/2011 7:34:41 PM : Underperform Start Price: $7.70 GENE Score: +138.43

Coming down

Recs

0
Member Avatar ferdicemara (< 20) Submitted: 5/15/2011 11:38:11 AM : Outperform Start Price: $7.73 GENE Score: -139.48

success

Recs

0
Member Avatar Lifeguru (65.81) Submitted: 4/9/2007 5:00:09 PM : Underperform Start Price: $7.10 GENE Score: +135.90

Junk

Recs

0
Member Avatar ctolbert (81.92) Submitted: 4/6/2007 7:39:22 PM : Underperform Start Price: $5.91 GENE Score: +134.51

Genetics companies are a hard sell and are too susceptible to market news to bank on.

Results 1 - 7 of 7

Featured Broker Partners


Advertisement